By Fineline Cube 
China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that it has received clinical clearance from the National Medical Products Administration (NMPA) for its AK2024 in HER2 positive advanced solid tumors.
AK2024: A Novel Anti-HER2 Antibody
AK2024 is a novel anti-HER2 antibody identified through trastuzumab-based functional screening. It demonstrates synergistic antitumor activity with trastuzumab. The drug selectively targets the extracellular domain of human epidermal growth factor receptor-2 (HER2) at an epitope distinct from those bound by either trastuzumab or pertuzumab.
Preclinical Study Results
Preclinical studies have shown that AK2024 effectively inhibits the proliferation of HER2-positive tumor cells. It exhibits synergistic effects with trastuzumab and enhances the antitumor efficacy of trastuzumab more potently than pertuzumab.-Fineline Info & Tech